JANSSEN DRAWS WARNING LETTER FOR RISPERDAL PROMOTION

Drug Industry Daily
KEYWORDS FDA / Warning
A A

The FDA’s Division of Drug, Marketing, Advertising and Communication (DDMAC) has issued a warning letter to Janssen Pharmaceutica regarding a “Dear Healthcare Provider” (DHP) letter that included misleading claims about the company’s atypical antipsychotic drug Risperdal.

To View This Article:

Login

Subscribe To Drug Industry Daily